Loading
NASDAQHealthcareBiotechnology
Latest quote
$17.88
+$0.47 · +2.70%
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Previous close
$17.88
+$0.47 · +2.70%
Regular session · ET · Market data may be delayed.
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $17.88
52-week range
Current $17.88
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
39
Expensive
Sentiment
58
Mixed
Risk
46
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $17.88
52-week range
Current $17.88
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 15.36M USD | 10.01M USD | 25.55M USD | 1.38M USD | 3.03M USD |
| Cost of goods sold | 3.56M USD | 315.44M USD | 326.39M USD | 243.01M USD | 169.39M USD |
| Gross profit | 11.8M USD | −305.43M USD | −300.84M USD | −241.62M USD | −166.36M USD |
| Research and development | 261.38M USD | 319.09M USD | 330.02M USD | 246.36M USD | 295.65M USD |
| Selling, general, and administrative | 56.71M USD | 80.24M USD | 78.58M USD | 69.33M USD | 59.75M USD |
| Operating expenses | 314.54M USD | 67.03M USD | 72.16M USD | 57.65M USD | 198.34M USD |
| Interest income | 27.04M USD | 34.75M USD | 31.05M USD | 8.79M USD | 830K USD |
| Depreciation and amortization | 3.56M USD | 5.46M USD | 5.27M USD | 4.13M USD | 3.93M USD |
| Operating income | −302.74M USD | −372.47M USD | −373M USD | −299.28M USD | −364.7M USD |
| Net income | −276.48M USD | −337.71M USD | −341.97M USD | −290.51M USD | −363.87M USD |
Company facts updated Oct 12, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI125.29M0.01%2.3T USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI85.8M0.87%9.87B USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM83.55M0.11%78.74B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF36.21M0.04%95.4B USD0.05%$235+0.80%
iShares Biotechnology ETFIBB23.11M0.22%10.82B USD0.44%$206.49+3.00%
iShares Russell 2000 Growth ETFIWO23.05M0.17%13.92B USD0.24%$356.78+0.94%
Dimensional - US Small Cap ETFDFAS21.94M0.06%33.87B USD0.31%$78.35+0.32%
T. Rowe Capital Appreciation Equity ETFTCAF17.55M0.19%9.11B USD0.31%$43.59+0.90%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFAST. Rowe Capital Appreciation Equity ETFTCAFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
